


Fondaparinux sodium



CAS

114870-03-0

Status

Commercial

[Inquiry](#)

Fondaparinux sodium is structurally close to heparin with only one more sulfate group. It is a selective factor Xa inhibitor which, by binding to antithrombin III, results in less thrombin formation and less thrombus growth. It is therefore used as an anticoagulant and antithrombotic. It is approved for the prophylaxis of thrombosis and pulmonary embolism in patients after major orthopedic surgery, as well as general surgical and medical patients. It is also used to treat deep vein thrombosis and pulmonary embolism, thrombophlebitis of the lower extremities, various infarcts and unstable angina pectoris.

Description

Formula $\text{C}_{31}\text{H}_{43}\text{N}_3\text{O}_{49}\text{S}_8 \cdot 10 \text{ Na}$

Molecular weight 1,728.08 g/mol

Molecular size small

Controlled Substance no

Precursor no

Indications Antithrombotic agents

Your Contact



Marius Hang

International Division

Director API Export

Midas Pharma GmbH

Rheinstr. 49

55218 Ingelheim

Germany

[Send E-Mail](#)

Disclaimer

The information contained herein is the proprietary information of Midas Pharma GmbH and its affiliates. This information is provided to you solely for your evaluation, to determine your interest in a potential business relationship with Midas Pharma GmbH and/or its affiliates. Midas Pharma GmbH excludes any express or implied representations, guarantees or warranties of whatsoever nature, including but not limited to the warranties for the completeness or accuracy of the information provided herein.

No information provided herein – including any reference to any product or service – constitutes an offer for sale, or shall be construed as representing an offer for sale. In particular, nothing herein should be construed as a promotion or advertisement for any product, or for the use of any product, that infringes valid patents and/or is not authorized by the laws and regulations of your country of residence.